Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
The Plasmodium falciparum serine repeat antigen (SERA) is one of the promising   blood-stage malarial vaccine candidates. In this study, recombinant Mycobacterium bovis   bacille Calmette-Guerin (rBCG) expressing the 22 kDa protein (SE22) from the 47 kDa Nterminal   domain of serine repeat antigen (SERA), generated in favour of mycobacterium   codon usage, elicited specific immune response in BALB/c mice with a mixed Th1/Th2 profile.   Immunized sera containing high levels of specific IgG1 and IgG2a against the epitope (as   determined by ELISA) were reactive with fixed P. falciparum merozoites as demonstrated by   indirect immunofluorescence assay (IFA). Furthermore, the lymphocyte proliferative response   to SE22 antigen from rBCG-immunized mice was higher than that of controls. The expression   of intracellular cytokines (IL-2, IL-4 and IFNγ) in CD4+- and CD8+-cells was also enhanced   following in-vitro stimulation with SE22. These findings indicate that a rBCG-based vaccine   candidate expressing a blood-stage antigen of P. falciparum could enhance both humoral and   cellular immune responses, thus paving the way for the rational use of rBCG as a vaccine   candidate against malaria.
Schools of Health Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
W H
WH
Teo
A A
AA
Nurul
M N
MN
Norazmi
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood / Q000276:immunology; D000917:Antibody Formation; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D001500:BCG Vaccine / Q000235:genetics / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003001:Cloning, Molecular; D016207:Cytokines / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli / Q000235:genetics / Q000378:metabolism; D019084:Fluorescent Antibody Technique, Indirect; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000097:blood; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000276:immunology; D017780:Malaria Vaccines / Q000235:genetics / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D010963:Plasmodium falciparum / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D001500:BCG Vaccine; D016207:Cytokines; D007074:Immunoglobulin G; D008222:Lymphokines; D017780:Malaria Vaccines; D014614:Vaccines, Synthetic; C043695:lymphocyte proliferation potentiating factors; C057495:serine repeat antigen, Plasmodium